MedTrace Logo

A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada

NCT02985450 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2021-11-03

Study results available
· View outcomes & findings →

Summary

(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B. (2) Adults with NAFLD who receive the HBV vaccine have reduced immunogenic responses in the setting of obesity (i.e., protective anti-HBs titres). Aims: (1) To determine the sero-prevalence of immunity against hepatitis B in a cohort of prospectively evaluated adult NAFLD patients. (2) To prospectively determine HBV vaccine responses (anti-HBs titres) in adult NAFLD patients.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Hepatitis B
  • Vaccine Reaction

Interventions

BIOLOGICAL

Engerix-B

Hepatitis B Vaccine

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Carla Coffin · University of Calgary

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985450 on ClinicalTrials.gov